2 Biotech Stocks Seeing Strong Gains

ICPT and NLNK are both surging up the charts in early trading

Sep 25, 2017 at 9:31 AM
facebook X logo linkedin


U.S. stocks are pulling back this morning as the dollar weakens. Among specific stocks in focus today are social media site Facebook Inc (NASDAQ:FB), as well as biotech stocks Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and NewLink Genetics Corp (NASDAQ:NLNK). Here's a closer look at what's moving shares of FB, ICPT, and NLNK. 

FB Shares Dip on Stock Plan Update

Facebook stock is down 0.6% at $169.48, after CEO Mark Zuckerberg announced he's dropping the company's plan to issue a new class of stock. Zuckerberg said FB's share price has appreciated enough that he can sell a large chunk of his stock to fund his philanthropic efforts while maintaining control of the company. The equity has gained over 31% in the past year, and could now be finding support atop its 50-day moving average. 

Meanwhile, short interest has been grinding higher on the security since hitting a record low in March. In the last reporting period alone, short interest rose almost 6% -- though these bearish bets still account for less than 1% of the total float. 

Intercept Replies to FDA Warning

Intercept Pharmaceuticals stock is up 7.2% at $66, after the company responded to the Food and Drug Administration's (FDA) warning of its liver drug, Ocaliva, saying it's taking steps to make sure the drug is prescribed and used properly. The shares still have plenty of ground to make up, though, as they were trading near $135 as recently as the end of July. Year-over-year, they're down over 63%. 

Most analysts are bullish on the stock, however. Specifically, ICPT has 10 "buy" or better ratings, versus five "hold" or worse recommendations. More telling still, the shares have an average 12-month price target of $157.76. 

NewLink Genetics Teams Up with AstraZeneca 

Shares of NewLink Genetics are up 6% at $11.65, after the company announced a clinical collaboration with AstraZeneca. NLNK stock has been all over the charts in 2017, trading as high as $25.16, with a year-to-date low of $5.90. Overall, the security is clinging to a small year-to-date lead. 

Plenty of traders foresee a pullback from NewLink Genetics, though. Short interest has been rising rapidly for months, and now more than 28% of the stock's float is sold short. Going by average daily volumes, this equates to almost 12 days' worth of buying power. 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI